| Semaglutide and NTproBNP in Obesity-Related HFpEF: Insights from STEP-HFpEF Program MC Petrie, BA Borlaug, J Butler, MJ Davies, DW Kitzman, SJ Shah, ... Journal of the American College of Cardiology, 2024 | 1 | 2024 |
| Sodium zirconium cyclosilicate in patients with HFrEF and hyperkalemia: REALIZE-K rationale, design, and baseline characteristics MN Kosiborod, D Cherney, K Connelly, AS Desai, PO Guimarães, L Kuthi, ... JACC: Heart Failure, 2024 | | 2024 |
| Semaglutide and Diuretic Use in Obesity-Related Heart Failure with Preserved Ejection Fraction: A Pooled Analysis of the STEP-HFpEF and STEP-HFpEF-DM trials SJ Shah, K Sharma, BA Borlaug, J Butler, M Davies, DW Kitzman, ... European Heart Journal, ehae322, 2024 | | 2024 |
| Baseline characteristics of patients with heart failure with mildly reduced or preserved ejection fraction: The FINEARTS‐HF trial SD Solomon, JW Ostrominski, M Vaduganathan, B Claggett, PS Jhund, ... European Journal of Heart Failure, 2024 | | 2024 |
| Fractal Dimension of -Fractal Functions Without Endpoint Conditions Gurubachan, V Chandramouli, S Verma Mediterranean Journal of Mathematics 21 (3), 71, 2024 | 1 | 2024 |
| Fractal Dimension of alpha-Fractal Functions Without Endpoint Conditions Gurubachan, V Chandramouli, S Verma MEDITERRANEAN JOURNAL OF MATHEMATICS 21 (3), 2024 | | 2024 |
| GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage B Park, E Bakbak, H Teoh, A Krishnaraj, F Dennis, A Quan, OD Rotstein, ... American Journal of Physiology-Heart and Circulatory Physiology 326 (5 …, 2024 | | 2024 |
| Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials J Butler, SJ Shah, MC Petrie, BA Borlaug, SZ Abildstrøm, MJ Davies, ... The Lancet 403 (10437), 1635-1648, 2024 | 5 | 2024 |
| A Retrospective Analysis of BCR-ABL-1 Kinase Domain Mutations in Frontline TKI Resistant Chronic Myeloid Leukemia Patients: A Single Centre Experience G Datta, SP Verma, AK Tripathi Indian Journal of Hematology and Blood Transfusion, 1-7, 2024 | | 2024 |
| Semaglutide in patients with obesity-related heart failure and type 2 diabetes MN Kosiborod, MC Petrie, BA Borlaug, J Butler, MJ Davies, GK Hovingh, ... New England Journal of Medicine 390 (15), 1394-1407, 2024 | 14 | 2024 |
| EFFECTS OF 1 MG ONCE-WEEKLY SEMAGLUTIDE ON FUNCTIONAL CAPACITY IN PATIENTS WITH TYPE 2 DIABETES AND PERIPHERAL ARTERIAL DISEASE: TRIAL DESIGN AND BASELINE CHARACTERISTICS FROM … MP Bonaca, AM Catarig, Y Hansen, K Houlind, B Ludvik, J Nordanstig, ... Journal of the American College of Cardiology 83 (13_Supplement), 2231-2231, 2024 | | 2024 |
| GLOBAL TRENDS IN VALVULAR HEART DISEASE-RELATED MORTALITY BY COUNTRY INCOME STATUS: ANALYSIS OF WHO MORTALITY DATABASE BETWEEN 2000-2019 M Hibino, H Ueyama, ME Halkos, KJ Grubb, R Verma, CA Nienaber, ... Journal of the American College of Cardiology 83 (13_Supplement), 2122-2122, 2024 | | 2024 |
| EFFECTS OF ICOSAPENT ETHYL ON VASCULAR REGENERATIVE CELLS IN INDIVIDUALS WITH ELEVATED TRIGLYCERIDES: INSIGHTS FROM THE IPE-PREVENTION CARDIOLINK-14 TRIAL E Bakbak, A Krishnaraj, DL Bhatt, B Park, Y Pan, D Terenzi, AI Bakbak, ... Journal of the American College of Cardiology 83 (13_Supplement), 2077-2077, 2024 | | 2024 |
| Effect of liraglutide on thigh muscle fat and muscle composition in adults with overweight or obesity: Results from a randomized clinical trial A Pandey, KV Patel, MW Segar, C Ayers, J Linge, OD Leinhard, SD Anker, ... Journal of Cachexia, Sarcopenia and Muscle, 2024 | | 2024 |
| Body mass index and cardiorenal outcomes in the EMPEROR‐Preserved trial: Principal findings and meta‐analysis with the DELIVER trial N Sattar, J Butler, MMY Lee, J Harrington, A Sharma, F Zannad, ... European Journal of Heart Failure, 2024 | 1 | 2024 |
| Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions J Harrington, GM Felker, JL Januzzi, CSP Lam, I Lingvay, NJ Pagidipati, ... Current Cardiology Reports, 1-11, 2024 | | 2024 |
| Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial E Bakbak, A Krishnaraj, DL Bhatt, A Quan, B Park, AI Bakbak, B Bari, ... Med, 2024 | | 2024 |
| Reductions in remnant cholesterol and VLDL cholesterol through inhibition of ANGPTL3 protein synthesis: an analysis from the TRANSLATE-TIMI 70 trial A Zimerman, SD Wiviott, JG Park, SA Murphy, X Ran, CR Bramson, ... European Journal of Preventive Cardiology, zwae090, 2024 | 1 | 2024 |
| Effect of dapagliflozin versus placebo on symptoms and 6-minute walk distance in patients with heart failure: the DETERMINE randomized clinical trials JJV McMurray, KF Docherty, RA de Boer, A Hammarstedt, DW Kitzman, ... Circulation 149 (11), 825-838, 2024 | 5 | 2024 |
| GLP-1 receptor agonists and vascular protection B Park, E Bakbak, H Teoh, A Krishnaraj, F Dennis, A Quan, OD Rotstein, ... American Journal of Physiology-Heart and Circulatory Physiology, 2024 | 1 | 2024 |
